ADVANCE ONLINE PUBLICATION

RESEARCH HIGHLIGHTS

Precision medicine for metastatic TNBC: the FUTURE is now

Julia Foldi¹ , Charles E. Geyer Jr^1,2,*

¹Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine and UPMC Hillman Cancer Center, Pittsburgh, PA, USA
²NSABP Foundation, Pittsburgh, PA, USA
* Correspondence: Charles E. Geyer Jr(charles.geyer@nsabp.org)

Despite well-described molecular heterogeneity of triple negative breast cancer (TNBC), management of metastatic disease primarily relies on cytotoxic chemotherapies, in some cases combined with immunotherapy, without consideration of molecular subtypes. In a recent Cell Research article, Liu et al. show the feasibility and promise of a precision medicine-guided treatment approach for heavily pretreated metastatic TNBC.

https://doi.org/10.1038/s41422-023-00815-1

FULL TEXT | PDF

Browse 197